Literature DB >> 2156278

Effects of m-chlorophenylpiperazine in normal subjects: a dose-response study.

R S Kahn1, S Wetzler, G M Asnis, M A Kling, R F Suckow, H M van Praag.   

Abstract

m-Chlorophenylpiperazine (MCPP), a direct 5HT receptor agonist, was administered orally to 20 normal subjects in two doses (0.25 and 0.5 mg/kg) in a placebo-controlled design. Behavioral responses; ACTH, cortisol, prolactin and MCPP blood level; temperature and pulse rate were measured over a 210-min period after administration of tablets. Non-linear dose-response relationships between MCPP and ACTH, cortisol and prolactin response were found. On the higher dose, a significant increase in the number of physical symptoms was also noted and three subjects (15%) had a panic attack, while one subject (5%) had a panic attack on the lower dose. No effects on other behavioral variables, pulse rate and temperature were found using either dose. These findings attest to the usefulness of MCPP as a challenge agent to assess 5HT receptor hypersensitivity when given at a low oral dose (i.e. around 0.25 mg/kg), and to assess 5HT receptor hyposensitivity when given at higher oral doses (i.e. around 0.5 mg/kg).

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2156278     DOI: 10.1007/BF02244603

Source DB:  PubMed          Journal:  Psychopharmacology (Berl)        ISSN: 0033-3158            Impact factor:   4.530


  28 in total

1.  Identification and distribution of 5-HT3 receptors in rat brain using radioligand binding.

Authors:  G J Kilpatrick; B J Jones; M B Tyers
Journal:  Nature       Date:  1987 Dec 24-31       Impact factor: 49.962

2.  Serotonin function in anxiety. II. Effects of the serotonin agonist MCPP in panic disorder patients and healthy subjects.

Authors:  D S Charney; S W Woods; W K Goodman; G R Heninger
Journal:  Psychopharmacology (Berl)       Date:  1987       Impact factor: 4.530

3.  Further studies of the putative serotonin agonist, m-chlorophenylpiperazine: evidence for a serotonin receptor mediated mechanism of action in humans.

Authors:  E A Mueller; D L Murphy; T Sunderland
Journal:  Psychopharmacology (Berl)       Date:  1986       Impact factor: 4.530

4.  Neuroendocrine effects of M-chlorophenylpiperazine, a serotonin agonist, in humans.

Authors:  E A Mueller; D L Murphy; T Sunderland
Journal:  J Clin Endocrinol Metab       Date:  1985-12       Impact factor: 5.958

5.  Neuroendocrine and behavioral effects of m-chlorophenylpiperazine administration in rhesus monkeys.

Authors:  J A Aloi; T R Insel; E A Mueller; D L Murphy
Journal:  Life Sci       Date:  1984-04-02       Impact factor: 5.037

6.  Research diagnostic criteria: rationale and reliability.

Authors:  R L Spitzer; J Endicott; E Robins
Journal:  Arch Gen Psychiatry       Date:  1978-06

7.  Serotonin-releasing effects of substituted piperazines in vitro.

Authors:  D J Pettibone; M Williams
Journal:  Biochem Pharmacol       Date:  1984-05-01       Impact factor: 5.858

8.  Trazodone and m-chlorophenylpiperazine. Concentration in brain and receptor activity in regions in the brain associated with anxiety.

Authors:  T M Smith; R F Suckow
Journal:  Neuropharmacology       Date:  1985-11       Impact factor: 5.250

9.  Long-term imipramine treatment enhances locomotor and food intake suppressant effects of m-chlorophenylpiperazine in rats.

Authors:  C S Aulakh; R M Cohen; J L Hill; D L Murphy; J Zohar
Journal:  Br J Pharmacol       Date:  1987-08       Impact factor: 8.739

10.  The corticotropin-releasing factor stimulation test. An aid in the evaluation of patients with Cushing's syndrome.

Authors:  G P Chrousos; H M Schulte; E H Oldfield; P W Gold; G B Cutler; D L Loriaux
Journal:  N Engl J Med       Date:  1984-03-08       Impact factor: 91.245

View more
  12 in total

1.  Daily administration of m-chlorophenylpiperazine to healthy human volunteers rapidly attenuates many of its behavioral, hormonal, cardiovascular and temperature effects.

Authors:  J Benjamin; B D Greenberg; D L Murphy
Journal:  Psychopharmacology (Berl)       Date:  1996-09       Impact factor: 4.530

Review 2.  The age of anxiety: role of animal models of anxiolytic action in drug discovery.

Authors:  John F Cryan; Fabian F Sweeney
Journal:  Br J Pharmacol       Date:  2011-10       Impact factor: 8.739

3.  Mono N-aryl ethylenediamine and piperazine derivatives are GABAA receptor blockers: implications for psychiatry.

Authors:  R F Squires; E Saederup
Journal:  Neurochem Res       Date:  1993-07       Impact factor: 3.996

4.  5-HT1C receptor antagonists have anxiolytic-like actions in the rat social interaction model.

Authors:  G A Kennett
Journal:  Psychopharmacology (Berl)       Date:  1992       Impact factor: 4.530

5.  A dose-response study of intravenous m-chlorophenylpiperazine in normal subjects.

Authors:  O Kalus; S Wetzler; R S Kahn; G M Asnis; H M van Praag
Journal:  Psychopharmacology (Berl)       Date:  1992       Impact factor: 4.530

6.  Inhibitory effect of ritanserin on the 5-hydroxytryptophan-mediated cortisol, ACTH and prolactin secretion in humans.

Authors:  M A Lee; J F Nash; M Barnes; H Y Meltzer
Journal:  Psychopharmacology (Berl)       Date:  1991       Impact factor: 4.530

7.  Effects of ipsapirone in healthy subjects: a dose-response study.

Authors:  R S Kahn; R Trestman; B A Lawlor; S Gabriel; M Davidson; L Siever
Journal:  Psychopharmacology (Berl)       Date:  1994-02       Impact factor: 4.530

8.  Haloperidol and clozapine treatment and their effect on M-chlorophenylpiperazine-mediated responses in schizophrenia: implications for the mechanism of action of clozapine.

Authors:  R S Kahn; L Siever; M Davidson; C Greenwald; C Moore
Journal:  Psychopharmacology (Berl)       Date:  1993       Impact factor: 4.530

9.  Effect of m-chlorophenylpiperazine on plasma arginine-vasopressin concentrations in healthy subjects.

Authors:  R S Kahn; M A Kling; S Wetzler; G M Asnis; H van Praag
Journal:  Psychopharmacology (Berl)       Date:  1992       Impact factor: 4.530

10.  Effect of pindolol on the prolactin response to d-fenfluramine.

Authors:  S B Park; P J Cowen
Journal:  Psychopharmacology (Berl)       Date:  1995-04       Impact factor: 4.530

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.